
Cleveland BioLabs, Inc. EBITDA 2011-2026 | CBLI
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Cleveland BioLabs, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -2.58 M | -2.35 M | -4.78 M | -5.58 M | -6.29 M | -10.7 M | -14.2 M | -22.6 M | -29.6 M | -24.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.35 M | -29.6 M | -12.3 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
1.19 M | $ 0.89 | - | $ 6.54 M | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
232 M | $ 22.2 | - | $ 3.68 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Edesa Biotech
EDSA
|
-6.83 M | $ 15.9 | - | $ 50.8 M | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Evogene Ltd.
EVGN
|
-31 M | $ 0.76 | - | $ 27.9 M | ||
|
Exelixis
EXEL
|
901 M | $ 44.69 | - | $ 12.1 B | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Galapagos NV
GLPG
|
-166 M | $ 27.86 | - | $ 2.69 B | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Grifols, S.A.
GRFS
|
595 M | $ 7.91 | - | $ 6.83 B | ||
|
Harmony Biosciences Holdings
HRMY
|
232 M | $ 31.05 | - | $ 1.79 B | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | ||
|
ImmuCell Corporation
ICCC
|
4.43 M | $ 8.44 | - | $ 76.2 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-9.75 M | - | -2.5 % | $ 5.88 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 101.57 | - | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Immuron Limited
IMRN
|
-2.87 M | $ 0.81 | 0.3 % | $ 9.47 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
Incyte Corporation
INCY
|
1.61 B | $ 99.1 | - | $ 19.3 B | ||
|
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | ||
|
InMed Pharmaceuticals
INM
|
-7.75 M | $ 0.7 | - | $ 1.71 M | ||
|
INmune Bio
INMB
|
-47.3 M | $ 1.33 | - | $ 32.9 M | ||
|
Innoviva
INVA
|
190 M | $ 23.05 | - | $ 1.55 B | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Innate Pharma S.A.
IPHA
|
-47.8 M | $ 1.48 | -0.67 % | $ 235 M | ||
|
Jaguar Health
JAGX
|
-44 M | $ 7.88 | - | $ 18.4 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | ||
|
KalVista Pharmaceuticals
KALV
|
-111 M | $ 26.67 | - | $ 1.44 B | ||
|
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | ||
|
Kamada Ltd.
KMDA
|
-696 K | $ 8.11 | - | $ 260 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 2.98 | - | $ 4.91 M | ||
|
Krystal Biotech
KRYS
|
167 M | $ 259.95 | - | $ 7.52 B | ||
|
Kazia Therapeutics Limited
KZIA
|
-7.74 M | $ 12.42 | - | $ 1.65 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
12.6 M | $ 224.86 | - | $ 4.11 B | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Liquidia Corporation
LQDA
|
-49.8 M | $ 38.15 | - | $ 3.28 B | ||
|
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
-70.5 M | $ 4.05 | - | $ 433 M | ||
|
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M |